Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Merck : MilliporeSigma Collaborates with LabCentral to Foster Biotech Startups

share with twitter share with LinkedIn share with facebook
share via e-mail
04/25/2017 | 02:07pm CEST

News Release

Your Contact

Karen Tiano +1 978 495 0093

April 25, 2017

MilliporeSigma Collaborates with LabCentral to Foster Biotech Startups
  • Company to provide expert guidance and counsel to biotech startups
  • New sponsorship to offer access to state-of-the-art collaborative laboratory

Billerica, Massachusetts, April 25, 2017 - MilliporeSigma announced today that the company will sponsor the Startup Program at LabCentral, a biotechnology incubator, in Cambridge, Massachusetts. LabCentral is a private, non-profit organization that provides entrepreneurs and innovative life-sciences startups with lab space and resources to nurture the next generation of biotech companies. It comprises approximately 125 scientists and entrepreneurs.

MilliporeSigma's collaboration with LabCentral, like its ongoing Emerging Biotech grant program, gives biotech startups access to process development tools, education programs and training to support their success and strengthen the biotech community.

"Innovation is at the heart of the life science industry and startups play an important role in developing new and often life-changing, scientific discoveries," said Udit Batra, member of the Executive Board, Merck KGaA, Darmstadt Germany and CEO, MilliporeSigma. "We are collaborating with LabCentral to be a resource for these emerging companies and to help them get the best start possible."

As a sponsor of the LabCentral Startup Program, MilliporeSigma will "adopt" a startup company which entitles the selected company to a priority spot and one- year prepaid lab bench in LabCentral's shared laboratory workspace. Candidates

Page 1 of 2

290 Concord Road Billerica, MA 01821 USA emdgroup.com

Contact: Karen Tiano [email protected]

+1 978 495 0093

[email protected]

News Release

can consult program rules and submit their application at emdmillipore.com/start- up-program. Submission close is July 2, 2017.

"This is an exciting time at LabCentral as we begin construction on our facility expansion, which will make room for an additional 30 startups," said LabCentral Co-Founder and President Johannes Fruehauf, M.D., Ph.D. "Today, LabCentral has become the de facto standard in co-working facilities for biotech startups. From the breadth and quality of our infrastructure and equipment, to our supportive services and programming, to the LabCentral Startup Program-our sponsors are critical partners. We are thrilled to welcome MilliporeSigma as a Gold sponsor, and look forward to a fruitful collaboration with the technical team."

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About the Life Science Business of Merck KGaA, Darmstadt, Germany

The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the

U.S. and Canada, has 19,000 employees and 65 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.

Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.

Merck KGaA, Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses - Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials - and generated sales of €15.0 billion in 2016. Around 50,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.

Merck KGaA, Darmstadt, Germany is the world's oldest pharmaceutical and chemical company - since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. The company holds the global rights to the name and the trademark "Merck" internationally except for the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Page 2 of 2

Merck KGaA published this content on 25 April 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 25 April 2017 12:07:16 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK KGAA
04/25 MERCK : MilliporeSigma Collaborates with LabCentral to Foster Biotech Startups
04/25 Fresenius picks up M&A pace with Akorn, Merck KGaA deals
04/25DJFRESENIUS : Makes Two Acquisitions to Boost Kabi Clinical Unit
04/24 MERCK : Darmstadt, Germany Divests Biosimilars Business to Fresenius
04/24DJFresenius Kabi To Strengthen And Diversify Product Portfolio By Acquiring Ako..
04/24 AWARE FOR ALL : CISCRP's Clinical Research Education Event Returning to Houston ..
04/20 MERCK : Researchers from Merck KGaA Describe Findings in Granulocytes (Compariso..
04/20 Merck to expand online business 'dramatically'
04/18 MERCK : Darmstadt, Germany Furthers Commitment Towards Elimination of Schistosom..
04/14 Slab Gel Electrophoresis Market 2017 - 3M Purification, Merck KGaA, AB Sciex,..
More news
Sector news : Specialty & Advanced Pharmaceuticals
10:10aDJASTRAZENECA : Profit Drops on Decline in Blockbuster-Drug Revenue -- Update
09:41aDJASTRAZENECA : Correction to AstraZeneca Profit Drops on Decline in Blockbuster-D..
09:26aDJBAYER : First-Quarter Net Profit Up 38% at EUR2.08 Billion -- Update
08:48aDJGLAXOSMITHKLINE : New Glaxo CEO Seeks Tighter Drug Focus -- WSJ
08:45aDJASTRAZENECA : Profit Drops on Decline in Blockbuster-Drug Revenue
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
06:29a Fresenius Medical (FMS) Acquires Akorn (AKRX) And Merck KGaA's (MKGAF) Biosim..
04/26 Fresenius Shows Biotech How To Get The Deals Done
04/25 FOCUS ON EUROPE : Gearing Up For Q1 Results!
04/15 The Market Is Going To Fall - My Dividend Growth Shopping List
03/31 AMERICAN ASSOCIATION FOR CANCER RESE : Combinations, Oncolytic Viruses, And More
Financials (€)
Sales 2017 15 585 M
EBIT 2017 3 307 M
Net income 2017 1 846 M
Debt 2017 9 705 M
Yield 2017 1,17%
P/E ratio 2017 25,21
P/E ratio 2018 21,36
EV / Sales 2017 1,52x
EV / Sales 2018 1,34x
Capitalization 13 945 M
More Financials
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 111 €
Spread / Average Target 2,5%
Consensus details
EPS Revisions
More Estimates Revisions
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA7.97%15 200
ABBVIE INC3.96%103 646
More Results